PMID- 18446669
OWN - NLM
STAT- MEDLINE
DCOM- 20080610
LR  - 20090626
IS  - 1521-0758 (Electronic)
IS  - 0191-3123 (Linking)
VI  - 32
IP  - 2
DP  - 2008 Mar-Apr
TI  - Contribution of cytogenetics to the management of poorly differentiated sarcomas.
PG  - 63-71
LID - 10.1080/01913120801897141 [doi]
AB  - Sarcomas constitute a heterogeneous group of rare tumors that in recent years 
      have been shown by cytogenetic analysis to have a remarkably high incidence of 
      specific and primary alterations. These genetic alterations not only have guided 
      molecular studies in establishing the underlying genes involved, thereby yielding 
      important pathogenetic information, but have also provided clinicians with a 
      valuable tool to add to their diagnostic armamentarium. The addition of molecular 
      cytogenetic (fluorescence in situ hybridization [FISH]) and molecular approaches 
      (reverse transcriptase-polymerase chain reaction [RT-PCR]) has further enhanced 
      the sensitivity and accuracy of detecting nonrandom chromosomal imbalances and/or 
      structural rearrangements in sarcomas, including assessment in formalin-fixed, 
      paraffin-embedded tissues. Poorly differentiated sarcomas represent a significant 
      challenge to the pathologist as these neoplasms lack an identifiable hematoxylin 
      and eosin-stained phenotype and often have lost diagnostic immunohistochemical or 
      ultrastructural features as well. In contrast, primary cytogenetic changes and 
      associated molecular events such as the 11;22 translocation in Ewing sarcoma are 
      retained as a given tumor metastasizes or becomes less differentiated, as their 
      presence appears to be vital for sustaining neoplastic transformation. 
      Consequently, demonstration of characteristic, tumor-specific chromosomal 
      aberrations is especially useful in the management of poorly differentiated 
      sarcomas.
FAU - Bridge, Julia A
AU  - Bridge JA
AD  - Department of Pathology & Microbiology, 983135 Nebraska Medical Center, Omaha, NE 
      68198-3135, USA. jbridge@unmc.edu
LA  - eng
GR  - P30 CA 3672/CA/NCI NIH HHS/United States
GR  - R01-CA89461/CA/NCI NIH HHS/United States
GR  - U-10-CA98543-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ultrastruct Pathol
JT  - Ultrastructural pathology
JID - 8002867
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Anaplasia
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis/*methods
MH  - DNA, Neoplasm/analysis
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Molecular Diagnostic Techniques/*methods
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sarcoma/diagnosis/*genetics/therapy
MH  - Soft Tissue Neoplasms/diagnosis/*genetics/therapy
EDAT- 2008/05/01 09:00
MHDA- 2008/06/11 09:00
CRDT- 2008/05/01 09:00
PHST- 2008/05/01 09:00 [pubmed]
PHST- 2008/06/11 09:00 [medline]
PHST- 2008/05/01 09:00 [entrez]
AID - 792115432 [pii]
AID - 10.1080/01913120801897141 [doi]
PST - ppublish
SO  - Ultrastruct Pathol. 2008 Mar-Apr;32(2):63-71. doi: 10.1080/01913120801897141.